Sunitinib Malate in Refractory Germ Cell Tumors

Phase 2 Terminated 5 enrolled M.D. Anderson Cancer Center Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate, SU011248) can control the disease in patients with germ cell tumors that are resistant to earlier treatment.

Timeline

Start: 2009-05
Primary completion: 2014-12
Completion: 2014-12

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Publications

Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 1;7:52. doi: 10.1186/s13045-014-0052-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	50 mg	Oral

Indications

No indication recorded.